Impact3 co-founder Kyle Reidhead discusses the future of the artificial intelligence revolution and investment opportunities in AI infrastructure in ‘Making Money’. Anthropic CEO Dario Amodei predicted on Wednesday that AI could help cure most diseases in the next five to 10 years, arguing that the advanced technology will change the way scientists study biology and medicine. The company announced the discovery led by Claude of a molecular machine that it believes could represent a new gene-editing mechanism, although Anthropic said its precise biological function is still unclear. “Its precise function, biotechnological utility (if any), or level of importance remains unclear, but at the very least it is work I would have been proud to do as a PhD student,” Amodei wrote in a broad area of research, Claude read the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out.” He said the company has repeatedly seen a pattern in which AI performance in new intellectual domains goes from weak to “superhuman” in just a few years. Anthropic CEO Dario Amodei predicted that AI could help cure most diseases in the next five to ten years. (Anna Moneymaker/Getty Images/Getty Images)”In 2023, the models struggled to do math at the level of an average high school student. In 2024, they started doing well in math competitions for the top high school students in the country, in 2025, they started solving minor open problems, in early 2026, major open problems, and in late 2026, they are starting to solve the few major open problems in all of mathematics. I think that AI for biology is on a similar exponential trend,” he said. Amodei pointed out that the main difference between biology and mathematics is that mathematics can be done purely theoretically and biology needs experimentation. He said that while some point to this to argue that AI’s usefulness in biology will be limited, his company believes the suspicion is misguided. He said humans can collaborate with AI to perform the experiments, validate key results within a few weeks and, if necessary, work with AI to repeat what they find. Irina Ghose, managing director of Anthropic PBC in India, left, and Dario Amodei, co-founder and CEO of Anthropic. (Samyukta Lakshmi/Bloomberg via Getty Images/Getty Images) “Eventually, it is possible that even Claude himself could conduct the experiments safely by autonomously controlling the laboratory equipment, with appropriate safeguards, but we are not doing that today,” he explained. Accelerating fundamental biology discoveries could broaden and accelerate the broader biomedical process by identifying new drug targets, therapies and research tools, he said. While it would not shorten clinical trials, it said it could produce more promising candidates for testing, emphasizing that any resulting treatment would still require standard testing and regulatory review. wrote.AUSTRALIAN PRIME MINISTER SAYS OPENAI AGENT ACCESSED GOVERNMENT HEALTH WEBSITE, RAISES ‘EXTREME CONCERN’ Anthropic CEO Dario Amodei, Chief Product Officer Mike Krieger and Head of Communications Sasha de Marigny during a press conference. (Julie Jammot/AFP / Getty Images)GET FOX BUSINESS ON THE GO BY CLICKING HERE “I am proud of the resources Anthropic has invested in accelerating the public benefits of AI across the life sciences, and we aim to grow our life sciences team and work with other scientists to extend this approach to a wide range of problems,” he added. Earlier on Wednesday, Amodei spoke to the UN Security Council about the need for the AI industry to establish international standards. and cooperation to manage the threats posed by rapid AI developments and capabilities.
